利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.028 秒)

    EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA
    3.
    发明申请
    EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA 审中-公开
    用于多发性骨髓瘤的生物骨髓细胞的筛查治疗

    公开(公告)号：US20110207627A1

    公开(公告)日：2011-08-25

    申请号：US13057978

    申请日：2009-08-12

    申请人： Lance A. Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    发明人： Lance A. Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    IPC分类号： C12Q1/02 ,  G01N33/566 ,  C40B30/04 ,  C12Q1/37 ,  C12Q1/48 ,  H01J49/26

    CPC分类号： G01N33/56972 ,  G01N33/5011 ,  G01N2333/70596 ,  G01N2510/00 ,  G01N2800/52

    摘要： Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.

    摘要翻译： 提供了选择多发性骨髓瘤患者的治疗方法。 在开始治疗方案之前，从患者中分离骨髓抽吸物并与一种或多种候选治疗剂一起温育。 该方法确定最有可能为特定个体产生最佳结果的治疗或疗法组合。 除了改善临床结果之外，这种诊断性评估通过避免无效疗法，大大降低了医疗保健成本。 还提供了用于鉴定多发性骨髓瘤治疗的筛选试验。

    mTOR pathway theranostic
    4.
    发明授权
    mTOR pathway theranostic 有权
    mTOR通路

    公开(公告)号：US08628931B2

    公开(公告)日：2014-01-14

    申请号：US12083866

    申请日：2006-10-18

    申请人： Lance A. Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    发明人： Lance A. Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    IPC分类号： G01N33/53 ,  G01N33/50 ,  G01N33/52

    CPC分类号： G01N33/6842 ,  G01N2800/52

    摘要： This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.

    摘要翻译： 本发明涉及例如用于预测受试者对化学治疗剂和/或受试者预后的反应的方法，包括测量mTOR途径的至少一个成员的磷酸化状态和/或至少一种成员 相互作用的多肽途径（例如Akt途径的成员或IRS途径的成员）与来自受试者的癌症组织或癌细胞样品中的基线值相比，其中与基线相比提高了磷酸化水平 值表明受试者是化疗药物的无反应者和/或预后不良。 还描述了在有需要的受试者中治疗癌症的方法，其中所述受试者表现出升高的磷酸化状态水平，包括施用一种或多种mTOR抑制剂和/或互连途径。

    Mtor Pathway Theranostic
    5.
    发明申请
    Mtor Pathway Theranostic 有权
    Mtor途径Theranostic

    公开(公告)号：US20090148859A1

    公开(公告)日：2009-06-11

    申请号：US12083866

    申请日：2006-10-18

    申请人： Lance A Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    发明人： Lance A Liotta ,  Emanuel F. Petricoin, III ,  Virginia Espina

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6842 ,  G01N2800/52

    摘要： This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.

    摘要翻译： 本发明涉及例如用于预测受试者对化学治疗剂和/或受试者预后的反应的方法，包括测量mTOR途径的至少一个成员的磷酸化状态和/或至少一种成员 相互作用的多肽途径（例如Akt途径的成员或IRS途径的成员）与来自受试者的癌症组织或癌细胞样品中的基线值相比，其中与基线相比提高了磷酸化水平 值表明受试者是化疗药物的无反应者和/或预后不良。 还描述了在有需要的受试者中治疗癌症的方法，其中所述受试者表现出升高的磷酸化状态水平，包括施用一种或多种mTOR抑制剂和/或互连途径。

    Hydrogel Nanoparticle Based Immunoassay
    6.
    发明申请
    Hydrogel Nanoparticle Based Immunoassay 有权
    水凝胶纳米粒子免疫测定

    公开(公告)号：US20110236999A1

    公开(公告)日：2011-09-29

    申请号：US13061507

    申请日：2009-08-26

    申请人： Lance A. Liotta ,  Alessandra Luchini ,  Emaneul F. Petricoin ,  Virginia Espina

    发明人： Lance A. Liotta ,  Alessandra Luchini ,  Emaneul F. Petricoin ,  Virginia Espina

    IPC分类号： G01N33/543 ,  B82Y15/00

    CPC分类号： G01N33/521 ,  G01N33/54333 ,  G01N33/54346

    摘要： An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.

    摘要翻译： 提供了在分析装置的流体流动路径内将多孔聚合物捕获纳米颗粒结合到样品采集容器中或预浸渍到多孔基质内的免疫测定装置。 这种在免疫测定装置内的捕获颗粒的并入提高了灵敏度，同时在加载免疫测定装置之前消除了样品预处理的要求。 优选的实施方案是含有捕获纳米颗粒的芯壳诱饵，其在一个步骤中在溶液中进行三个功能：a）分子筛分，b）目标分析物螯合和浓缩，以及c）防止降解。 捕获颗粒的聚合物基质可以由具有结构单体和亲和单体的共聚物制成，亲和单体具有将分析物吸引到捕获颗粒的性质。 该设备可用于生物医学应用的护理点诊断分析以及环境，病原体和化学或生物威胁鉴定的现场部署测定。

    Hydrogel nanoparticle based immunoassay
    7.
    发明授权
    Hydrogel nanoparticle based immunoassay 有权
    基于水凝胶纳米颗粒的免疫测定

    公开(公告)号：US09012240B2

    公开(公告)日：2015-04-21

    申请号：US13061507

    申请日：2009-08-26

    申请人： Lance A. Liotta ,  Alessandra Luchini ,  Emanuel F. Petricoin ,  Virginia Espina

    发明人： Lance A. Liotta ,  Alessandra Luchini ,  Emanuel F. Petricoin ,  Virginia Espina

    IPC分类号： G01N33/549 ,  G01N33/53 ,  G01N33/544 ,  G01N33/558 ,  G01N33/52 ,  G01N33/543

    CPC分类号： G01N33/521 ,  G01N33/54333 ,  G01N33/54346

    摘要： An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.

    摘要翻译： 提供了在分析装置的流体流动路径内将多孔聚合物捕获纳米颗粒结合到样品采集容器中或预浸渍到多孔基质内的免疫测定装置。 这种在免疫测定装置内的捕获颗粒的并入提高了灵敏度，同时在加载免疫测定装置之前消除了样品预处理的要求。 优选的实施方案是含有捕获纳米颗粒的芯壳诱饵，其在一个步骤中在溶液中进行三个功能：a）分子筛分，b）目标分析物螯合和浓缩，以及c）防止降解。 捕获颗粒的聚合物基质可以由具有结构单体和亲和单体的共聚物制成，亲和单体具有将分析物吸引到捕获颗粒的性质。 该设备可用于生物医学应用的护理点诊断分析以及环境，病原体和化学或生物威胁鉴定的现场部署测定。

    POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS
    8.
    发明申请
    POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS 审中-公开
    暴露后预防和治疗感染

    公开(公告)号：US20110046039A1

    公开(公告)日：2011-02-24

    申请号：US12530538

    申请日：2008-03-06

    申请人： Serguei G. Popov ,  Taissia Popov ,  Virginia Espina ,  Charles Bailey ,  Lance A. Liotta ,  Emanuel Petricoin

    发明人： Serguei G. Popov ,  Taissia Popov ,  Virginia Espina ,  Charles Bailey ,  Lance A. Liotta ,  Emanuel Petricoin

    IPC分类号： A61K38/07 ,  A61P31/04

    CPC分类号： A61K45/06 ,  A61K31/496 ,  A61K2300/00

    摘要： The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase ¼, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.

    摘要翻译： 本发明提供用于鉴定用于预防和/或治疗炭疽和类似疾病的药剂的方法和材料。 实施例提供用于研究非致死和致死性暴露于炭疽和类似疾病载体的菌株和模型系统。 实施例提供了用于使用菌株和模型系统进行差异分析的材料和方法，例如蛋白质组学分析，例如分化磷酸化分析，以靶向鉴定和治疗发现和发展。 实施方案提供了药学上可接受的组合物，以及使用它们来预防和/或治疗炭疽和类似疾病的方法，其包括降低半胱天冬酶（例如YVAD）的活性的试剂和/或增加AKT磷酸化的试剂，例如 在特定实施方案中，IB-MECA或Cl-IB-MECA，以及抗生素，如环丙沙星。 还提供了包括其的套件，以及其他。